Cargando…
Antisense oligonucleotide treatment produces a type I interferon response that protects against diet-induced obesity
OBJECTIVE: In mouse models, deficiency of TTC39B (T39) decreases hepatic lipogenic gene expression and protects against diet-induced steatohepatitis. While assessing the therapeutic potential of antisense oligonucleotides (ASOs) targeting T39, we discovered an unexpected weight loss phenotype. The o...
Autores principales: | McCabe, Kristin M., Hsieh, Joanne, Thomas, David G., Molusky, Matthew M., Tascau, Liana, Feranil, Jun B., Qiang, Li, Ferrante, Anthony W., Tall, Alan R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036698/ https://www.ncbi.nlm.nih.gov/pubmed/32180554 http://dx.doi.org/10.1016/j.molmet.2020.01.010 |
Ejemplares similares
-
Metformin and AMP Kinase Activation Increase Expression of the Sterol Transporters ABCG5/8 (ATP-Binding Cassette Transporter G5/G8) With Potential Antiatherogenic Consequences
por: Molusky, Matthew M., et al.
Publicado: (2018) -
Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment
por: Cao, Yang, et al.
Publicado: (2017) -
Antisense Oligonucleotide Technologies to Combat Obesity and Fatty Liver Disease
por: Keating, Michael F., et al.
Publicado: (2022) -
The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012) -
Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)